Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Naronapride in Idiopathic or Diabetic Gastroparesis
NCT05621811Phase 2Completed
- Sponsor
- Dr. Falk Pharma GmbH
- Start
- Jan 2023
- Primary completion
- Aug 2025
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 2, randomised, double-blind trial of naronapride in gastroparesis (4 arms), sponsored by Dr. Falk Pharma GmbH. Primary endpoint: American Neurogastroenterology and Motility Society Gastroparesis Cardinal Symptom Index - Daily Diary Total Score at 12 weeks. Started Jan 2023; status: completed.
02
Drugs
naronapride
03
Conditions
gastroparesis
Beyond the preview
Go deeper on NCT05621811.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05621811.